Fecal B-cell-activating factor as a new noninvasive marker in the evaluation of ulcerative colitis Egyptian patients: a comparative cross-sectional study

Background and aim Diagnosis of ulcerative colitis (UC) is suspected clinically and confirmed through endoscopic biopsy. It can be followed-up and assessed by noninvasive biomarkers such as fecal calprotectin. Recently, B-cell-activating factor (BAFF) has been proposed to be a regulator of B-cell an...

Full description

Saved in:
Bibliographic Details
Main Authors: Hany A Hussein (Author), Rasha S Mohamed (Author)
Format: Book
Published: SpringerOpen, 2019-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8e5e82daf737454c93fa285a4992cce8
042 |a dc 
100 1 0 |a Hany A Hussein  |e author 
700 1 0 |a Rasha S Mohamed  |e author 
245 0 0 |a Fecal B-cell-activating factor as a new noninvasive marker in the evaluation of ulcerative colitis Egyptian patients: a comparative cross-sectional study 
260 |b SpringerOpen,   |c 2019-01-01T00:00:00Z. 
500 |a 1110-7782 
500 |a 2090-9098 
500 |a 10.4103/ejim.ejim_118_19 
520 |a Background and aim Diagnosis of ulcerative colitis (UC) is suspected clinically and confirmed through endoscopic biopsy. It can be followed-up and assessed by noninvasive biomarkers such as fecal calprotectin. Recently, B-cell-activating factor (BAFF) has been proposed to be a regulator of B-cell and T-cell immune responses and to be associated with inflammatory processes in autoimmunity. The aim of our study was to clarify the role of fecal BAFF as a simple predictor for disease activity and severity in patients with UC. Patients and methods Fifty Egyptian patients with UC were divided into two groups: group I including 40 patients with active UC (newly diagnosed) and group II including 10 patients with inactive UC (previously diagnosed); disease activity was assessed according to the Mayo activity scoring index; fecal BAFF and fecal calprotectin were measured for all patients using enzyme-linked immunosorbent assay. Results Significantly higher levels of Fecal BAFF and fecal calprotectin were found among patients with active UC, as compared with inactive UC patients. Fecal BAFF more than or equal to 50 μg/g had 97.5% sensitivity and 100% specificity in predicting disease activity in comparison with fecal calprotectin, which had a sensitivity and specificity of 90% at a cut off value more than or equal to 47 μg/g. In predicting disease severity, fecal BAFF more than or equal to 340 μg/g had a sensitivity of 95% and specificity of 100%, while fecal calprotectin more than or equal to 170 μg/g had a sensitivity of 80% and specificity of 95%. Conclusion Fecal BAFF is more sensitive and specific in predicting UC activity and severity than fecal calprotectin. 
546 |a EN 
690 |a biomarker 
690 |a fecal b-cell-activating factor 
690 |a fecal calprotectin 
690 |a inflammatory bowel disease 
690 |a ulcerative colitis 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n The Egyptian Journal of Internal Medicine, Vol 31, Iss 4, Pp 563-572 (2019) 
787 0 |n http://www.esim.eg.net/article.asp?issn=1110-7782;year=2019;volume=31;issue=4;spage=563;epage=572;aulast=Hussein 
787 0 |n https://doaj.org/toc/1110-7782 
787 0 |n https://doaj.org/toc/2090-9098 
856 4 1 |u https://doaj.org/article/8e5e82daf737454c93fa285a4992cce8  |z Connect to this object online.